Company / Current Liabilities
Axsome Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$378.8M
FY2025
5-year range
$23.1M / $378.8M
FY2021-FY2025
Trend
+64.6%
vs FY2024
Sector context
#41 of 213
Health Care
What the data says
Axsome Therapeutics, Inc.'s current liabilities of $379M is higher than 81% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 4 consecutive years, from $23M in FY2021 to $379M in FY2025.
Based on SEC 10-K filings.
$379M in FY2025 with a 5-year CAGR of +74.5%. Top quartile in the Health Care sector.
Increased from $139M to $379M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +57.7%
- 5-Year CAGR
- +74.5%
- 10-Year CAGR
- -
Sector benchmark
-76.1% below sector average
Key checks
Key Insights
- Axsome Therapeutics, Inc.'s current liabilities has grown for 4 consecutive years.
- 5-year CAGR of +74.5%, indicating consistent growth.
- In FY2025, current liabilities increased 64.6% year-over-year.
- Ranks #41 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $378.8M | +64.6% |
| FY2024 | $230.1M | +65.7% |
| FY2023 | $138.9M | +43.8% |
| FY2022 | $96.6M | +318.6% |
| FY2021 | $23.1M | -1.6% |
| FY2020 | $23.4M | -4.3% |
| FY2019 | $24.5M | +126.3% |
| FY2018 | $10.8M | -11.1% |
| FY2017 | $12.2M | +69.8% |
| FY2016 | $7.2M | +172.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026